Loading
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Latest quote
$7.75
−$0.43 · -5.26%
After-hours
$7.75
$0.00 · 0.00%
Sep 16, 7:30 PM ET
Regular session · ET · Market data may be delayed.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Day range
Current $7.75
52-week range
Current $7.75
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
38
Expensive
Sentiment
60
Mixed
Risk
40
Moderate Risk
Momentum
79
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Day range
Current $7.75
52-week range
Current $7.75
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 9M USD | — | — | — |
| Gross profit | 9M USD | — | — | — |
| Research and development | 73.97M USD | 59.04M USD | 33.89M USD | 30.52M USD |
| Selling, general, and administrative | 27.81M USD | 19.16M USD | 14.51M USD | 9.45M USD |
| Operating expenses | 101.78M USD | 78.19M USD | 48.4M USD | 39.97M USD |
| Interest income | 13.09M USD | 9.63M USD | 2.43M USD | 465K USD |
| Interest expense | 697K USD | 2.37M USD | 7.79M USD | 241K USD |
| Depreciation and amortization | 213K USD | 167K USD | 162K USD | 129K USD |
| Operating income | −92.78M USD | −78.19M USD | −48.4M USD | −39.97M USD |
| Net income | −80.61M USD | −71.11M USD | −63.85M USD | −39.72M USD |
Company facts updated Sep 17, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$34.00
338.71% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI10.84M0.00%2.3T USD0.03%$371.26-0.42%
iShares Russell 2000 ETFIWM7.59M0.01%79.89B USD0.19%$283.92-0.43%
Vanguard Extended Market ETFVXF3.53M0.00%95.4B USD0.05%$234.39-0.32%
State Street SPDR S&P Pharmaceuticals ETFXPH3.2M0.54%570.34M USD0.35%$66.790.00%
Vanguard U.S. Momentum Factor ETFVFMO3.13M0.16%1.9B USD0.13%$224.13-0.13%
iShares Russell 2000 Value ETFIWN2.41M0.02%14.31B USD0.24%$215.86-0.84%
iShares Biotechnology ETFIBB1.96M0.02%10.45B USD0.44%$202.4+0.20%
Vanguard Russell 2000 ETFVTWO1.92M0.01%18B USD0.06%$115.07-0.43%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHVanguard U.S. Momentum Factor ETFVFMOiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
